

Opto Circuits' H1FY13 consolidated net sales at Rs. 1322 crs, Net Profit at Rs. 254 crs

Bengaluru, India | 12 November 2012

Opto Circuits (India) Ltd., a leading developer and manufacturer of medical equipment and interventional devices for the global markets, today announced its financial results for the second quarter and half year ending September 30, 2012.

Highlights: Consolidated Sales & Profits

	H1FY13	Change
	Rs. Crs.	Y-o-Y
Net Sales	1322	22%
EPS (Rs.)	10.49	7%
Profitability		
Gross Profit	44%	
Operating Profit	27%	
Net Profit	19%	
Segment Contribution		
Medical Equipment & Consumables [Non Invasive]	1069	21%
Interventional Devices & Tools [Invasive]	243	29%
Non Medical	10	13%

Highlights: Consolidated Balance Sheet

		H1FY13	FY12
Net Worth	Rs. Crs.	1990	1699
Net Block		834	754
Net Operating Cycle	Days	199	178

Management Comment:

Vinod Ramnani, Chairman and Managing Director: "Our revenue performance for the second quarter of FY13 has been moderate but on a half-yearly basis, we've performed satisfactorily. Our Malaysian facilities for the non invasive business have been rendered operational in the first half and many cost-conscious customer segments have become accessible. I am, therefore, confident of a strong second half in FY13."

Disclaimer: Statements made in this document describing the company's objectives, projections, estimates, expectations may be "Forward-looking Statements" within the meaning of all applicable securities' laws and regulations. Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting demand, supply and price conditions in the domestic and overseas markets in which the Company operates, changes in government regulations, tax laws, other statutes and other incidental factors.

NSE Symbol: OPTOCIRCUI
BSE Code: 532391

Market Cap: Rs. 3142 crs*
[*As per the BSE closing price as on 28th September 2012]

Headquarters:
Bengaluru, Karnataka, India

Industry: Medical Technology

Key Products: AEDs, Patient Monitors, Cardiac Monitors, Vascular Diagnostics, Angioplasty Devices

- FY2012 -

Consolidated Financials:
Net Sales - Rs. 2357 crs
Net Profit - Rs. 572 crs
EPS - Rs. 23.6

Global Patents:
193 (+108 pending applications)

Employee Strength: ~1840

Quarter II Business Highlights:

Opto Cardiac Care Ltd. [OCCL]

- Unetixs Vascular received CE mark to market and sell its USFDA listed *Revo® 1100* in Europe. The product enables vascular technologists to perform noninvasive tests to detect Peripheral Arterial Disease (PAD).
- Cardiac Science won large orders and tenders in India, Israel, Romania and UK for AEDs; AMDL bagged and executed a prestigious AED tender from the Indian Army's Northern Command.

Opto Eurocor Healthcare Ltd. [OEHL]

- Company launched its first Sirolimus Drug Eluting Stent (DES), *E-MAGIC® Plus*, in India on receipt of Drug Controller General of India (DCGI) license to sell and market the product in the country.
- Eurocor announced the successful start of the DEBIFU Registry. This prospective multicenter German registry is designed to assess the safety and efficacy of the drug-eluting balloon *DIOR®* in the treatment of bifurcation lesions of all Medina classes. Under the direction of Principal Investigator, Dr. Hubertus von Korn, Hospital Hetzelstift, Neustadt an der Weinstraße (Germany), this registry is enrolling 100 patients at four German sites.

About: Opto Circuits (India) Ltd.

Opto Circuits (India) Ltd. (OCI) is a vertically integrated multinational medical technology Group that specializes in primary, acute and critical care products for the global markets. Group companies such as [Cardiac Science](#), [Criticare](#), [Eurocor](#), [Mediaid](#), [AMDL](#) and [Unetixs Vascular](#) are leaders in cardiac and vital signs monitors, emergency cardiac care equipment, vascular treatments and sensing technologies. Our USFDA listed and CE marked products are marketed in more than 150 countries and sold through direct and indirect sales channels across many emerging and developing economies.

We've been ranked in Forbes' *Asia's 200 Best under a Billion* lists in 2008, 2009 and 2011.

For more information, please visit www.optoindia.com.

Contact:

OCI: Media Queries: media@optoindia.com | Investor Queries | ir@optoindia.com | +91 80 2852 8088

Adfactors PR: Neha Goenka: neha.goenka@adfactorspr.com | +91 22 6757 4332

Disclaimer: Statements made in this document describing the company's objectives, projections, estimates, expectations may be "Forward-looking Statements" within the meaning of all applicable securities' laws and regulations. Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting demand, supply and price conditions in the domestic and overseas markets in which the Company operates, changes in government regulations, tax laws, other statutes and other incidental factors.